Linagliptin
Brand name: Tradjenta
Rank #46 of 500 drugs by total cost
$403.8M
Total Cost
519,439
Total Claims
$403.8M
Total Cost
16,484
Prescribers
$777
Cost per Claim
39,375
Beneficiaries
818,411
30-Day Fills
$24K
Avg Cost/Provider
32
Avg Claims/Provider
About Linagliptin
Linagliptin (sold as Tradjenta) was prescribed 519,439 times by 16,484 Medicare Part D providers in 2023, costing the program $403.8M. At $777 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 43 | Osimertinib Mesylate (Tagrisso) | $436.5M | 25,273 |
| 44 | Levothyroxine Sodium (Levothyroxine Sodium) | $435.3M | 20,209,418 |
| 45 | Deutetrabenazine (Austedo) | $404.1M | 60,532 |
| 46 | Linagliptin (Tradjenta) | $403.8M | 519,439 |
| 47 | Macitentan (Opsumit) | $394.6M | 30,889 |
| 48 | Insulin Detemir (Levemir Flexpen) | $376.5M | 548,216 |
| 49 | Aripiprazole (Aripiprazole) | $373.1M | 1,494,971 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology